Latest news with #CanaccordGenuity
Yahoo
9 hours ago
- Business
- Yahoo
Penumbra, Inc. to Present at the Canaccord Genuity 45th Annual Growth Conference
ALAMEDA, Calif., July 30, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025. Event: Canaccord Genuity 45th Annual Growth Conference Date: Tuesday, August 12, 2025 Time: 12:30pm ET/9:30am PT A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at The webcast will be available on the company's website for at least two weeks following the event. About Penumbra Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit and connect on Instagram, LinkedIn and X. Investor RelationsPenumbra, View original content to download multimedia: SOURCE Penumbra, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 hours ago
- Business
- Yahoo
Metallic Minerals Closes C$6 Million Brokered Private Placement Financing
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / / July 30, 2025 / Metallic Minerals Corp. (TSX-V:MMG)(OTCQB:MMNGF)(FSE:9MM1) (the "Company" or "Metallic") is pleased to announce that it has completed its previously announced brokered private placement financing (the "Offering"), including the exercise in full of the over-allotment option, for total gross proceeds of C$6,000,024 from the sale of 25,000,100 units of the Company (each, a "Unit") at a price of C$0.24 per Unit. Each Unit consists of one common share of the Company (each, a "Common Share") and one-half of one common share purchase warrant of the Company (each whole warrant, a "Warrant"). Each Warrant entitles the holder to purchase one Common Share at a price of C$0.34 at any time on or before July 30, 2027. Cormark Securities Inc., as lead agent, and Canaccord Genuity Corp., SCP Resource Finance LP, and Beacon Securities Limited, acted as agents in connection with the Offering (collectively, the "Agents"). The Units were sold in Canada in accordance with the listed issuer financing exemption under National Instrument 45-106 - Prospectus Exemptions, as amended by Coordinated Blanket Order 45-935 - Exemptions from Certain Conditions of the Listed Issuer Financing Exemption. The Common Shares and Warrants are freely tradeable in Canada in accordance with applicable Canadian securities legislation. The Units were also sold in the United States pursuant to one or more exemptions from the registration requirements of the United States Securities Act of 1933, as amended(the "U.S. Securities Act") and in offshore jurisdictions in accordance with applicable securities legislation. There is an offering document related to the Offering that can be accessed under the Company's profile at and on the Company's website at: (the "Offering Document"). The Company intends to use the net proceeds of the Offering to advance its La Plata copper-silver-gold-PGE project located in southwestern Colorado, USA, exploration at its Keno Silver project and other properties in Yukon, Canada, and for working capital and general corporate purposes, as described further in the Offering Document. Newmont Corporation, through its wholly-owned subsidiary, Newcrest International Pty Ltd., ("Newmont") has indicated that it intends to exercise its participation rights pursuant to the investor rights agreement with the Company dated May 18, 2023, to maintain its pro rata shareholding in the Company in connection with the Offering. No commission or other fees will be made to the Agents in connection with any participation by Newmont. To accommodate participation by management and insiders, along with the anticipated participation of Newmont (an insider of the Company), a separate non-brokered private placement is expected to follow which shall constitute a related party transaction pursuant to Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company is exempt from the requirements to obtain a formal valuation and minority shareholder approval in connection with the participation of the related parties in the private placements in reliance on the exemptions contained in sections 5.5(b) and 5.7(1)(a) of MI 61-101, respectively. The Company did not file a material change report at least 21 days before the expected closing date of the Offering as the insider participation had not been confirmed at that time and the Company wished to close the Offering as expeditiously as possible. Any securities issued to the foregoing management and insiders under the current Offering or the subsequent private placement will be subject to a hold period expiring four months and one day following the issue date. As consideration for their services under the Offering, the Agents received aggregate cash fees of C$247,530.24 and were issued at total of 1,031,375 non-transferable broker warrants of the Company (the "Broker Warrants"). Each Broker Warrant is exercisable into one Common Share at a price of C$0.34 per Common Share at any time on or before July 30, 2027. In connection with the Offering, the Company has also paid finder's fees totaling $29,000 to certain finders other than the Agents. This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons, absent registration or any applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. About Metallic Minerals Corp. Metallic Minerals Corp. is a resource-stage mineral exploration company, focused on copper, silver, gold, platinum group elements, and other critical minerals at the La Plata project in southwestern Colorado and the Keno Silver project adjacent to Hecla Mining's Keno Hill silver operations in the Yukon Territory. The Company is also one of the largest holders of alluvial gold claims in the Yukon and is building a production royalty business by partnering with experienced mining operators. Metallic Minerals is led by a team with a track record of discovery and exploration success on several major precious and base metal deposits in North America, as well as having large-scale development, permitting and project financing expertise. The Metallic Minerals team is committed to responsible and sustainable resource development and has worked closely with Canadian First Nation groups, U.S. Tribal and Native Corporations, and local communities to support successful project development. FOR FURTHER INFORMATION, PLEASE CONTACT: and info@ Phone: 604-629-7800Toll Free: 1-888-570-4420 Forward-Looking Statements This news release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts including, without limitation, statements regarding potential mineralization, title, expected results of operations, as well as financial position, prospects, and future plans and objectives of the Company are forward-looking statements that involve various risks and uncertainties. Although Metallic Minerals believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Forward-looking statements are based on a number of material factors and assumptions. Factors that could cause actual results to differ materially from those in forward-looking statements include failure to obtain necessary approvals, changes in project parameters as plans continue to be refined, results of future resource estimates, future metal prices, availability of capital and financing on acceptable terms, general economic, market or business conditions, risks associated with regulatory changes, defects in title, availability of personnel, materials and equipment on a timely basis, accidents or equipment breakdowns, uninsured risks, unanticipated environmental impacts on operations and costs to remedy same and other exploration or other risks detailed herein and from time to time in the filings made by the Company with securities regulators. Readers are cautioned that mineral resources that are not mineral reserves do not have demonstrated economic viability. Mineral exploration, development of mines and mining operations is an inherently risky business. Accordingly, the actual events may differ materially from those projected in the forward-looking statements. For more information on Metallic Minerals and the risks and challenges of their businesses, investors should review their annual filings that are available at Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE: Metallic Minerals Corp. View the original press release on ACCESS Newswire
Yahoo
17 hours ago
- Business
- Yahoo
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
NEEDHAM, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel's President and Chief Executive Officer, will present at the Canaccord Genuity 45th Annual Growth Conference, being held on August 12-14, 2025 in Boston, MA. Date: Wednesday, August 13, 2025Time: 2:00-2:25PM ESTWebcast Link: Canaccord Genuity / Candel Presentation A webcast of the presentation will be available by selecting Events and Presentations under the News & Events tab in the Investors section on A replay of the webcast will be archived for up to 90 days following the session date. About Candel Therapeutics Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of CAN-2409 in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled phase 3 clinical trial of CAN-2409 in localized prostate cancer, conducted under a Special Protocol Assessment (SPA) agreed with the U.S. Food and Drug Administration (FDA). In May 2025, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CAN-2409 for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease. CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma (rHGG). Initial results were published in Nature and CAN-3110 received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel's enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. For more information about Candel, visit: Forward-Looking Statements This press release includes certain disclosures that contain 'forward-looking statements,' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs; expectations regarding the therapeutic benefit of the Company's platforms; and expectations regarding the potential benefits conferred by Regenerative Medicine Advanced Therapy Designation, Fast Track Designation, Orphan Drug Designation or Orphan Designation. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company's programs; that final data from the Company's preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company's ability to efficiently discover and develop product candidates; the Company's ability to obtain and maintain regulatory approval of product candidates; the Company's ability to maintain its intellectual property; the implementation of the Company's business model, including strategic plans for the Company's business and product candidates; and other risks identified in the Company's filings with the U.S. Securities and Exchange Commission (SEC), including the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Investor ContactTheodore JenkinsVice President, Investor Relations and Business DevelopmentCandel Therapeutics, Media ContactBen ShannonVice PresidentICR Healthcare CandelPR@ produjo un error al recuperar la información Inicia sesión para acceder a tu portafolio Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información
Yahoo
2 days ago
- Business
- Yahoo
Canaccord Genuity Reiterates Buy Rating on Fractyl Health (GUTS)
Fractyl Health, Inc. (NASDAQ:GUTS) is one of the 11 Best New Penny Stocks to Buy Right Now. On July 18, Canaccord Genuity reiterated its 'Buy' rating on Fractyl Health, Inc. (NASDAQ:GUTS) with a price target of $12. This decision came after the company had shared new data from its Phase 3 trial of its lead product candidate, Revita. A medical laboratory surrounded by advanced equipment, symbolizing the company's cutting-edge innovation in healthcare. Canaccord Genuity had follow-up discussions with several physicians following the data presented by Fractyl Health, Inc. (NASDAQ:GUTS) from the open-label group of its ongoing Phase 3 trial for Revita in weight maintenance at the American Diabetes Association meeting. These physicians who were consulted by the investment firm were all from large academic hospitals in the US. The physicians had different opinions on the mechanism behind the Revita procedure and the potential market size. However, they all agreed that controlled data is needed to fully assess the clinical profile. The physicians said the main concern is the durability of the effect. Canaccord pointed out that even conservative market share estimates from the physicians surpassed the firm's current modeling expectations. Canaccord Genuity expects Revita to reach 1% peak penetration in the weight maintenance population with a 60% probability of success. The investment firm projects that peak sales could reach $400 million in 2031. Fractyl Health, Inc. (NASDAQ:GUTS) is a metabolic therapeutics company focused on pursuing therapies that target root causes of obesity and type 2 diabetes. While we acknowledge the potential of GUTS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Business Wire
2 days ago
- Business
- Business Wire
Electromed, Inc. to Participate in the Canaccord Genuity 45 th Annual Growth Conference
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. ('Electromed' or the 'Company') (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that Company management will participate in the Canaccord Genuity 45 th Annual Growth Conference, which will be held August 12-14, 2025 in Boston, MA. Electromed President and Chief Executive Officer Jim Cunniff, and Chief Financial Officer Brad Nagel will present on Tuesday, August 12 at 12:30 pm ET. Interested parties may access a live webcast of the presentation using the following link: Electromed CG Presentation. The link will also be posted on the Electromed Investor Relations website under Events & Presentations. Institutional investors may request one-on-one meetings through Canaccord Genuity. About Electromed, Inc. Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest ® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992. Further information about Electromed can be found at
